LogicBio Therapeutics, Inc.

NasdaqGM:LOGC Stock Report

Market Cap: US$68.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

LogicBio Therapeutics Management

Management criteria checks 1/4

Key information

Fred Chereau

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage24.3%
CEO tenure6.6yrs
CEO ownership0.8%
Management average tenure1.8yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion

Oct 03

Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

Aug 20
Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 18
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

LogicBio GAAP EPS of -$0.15, revenue of $3.2M

Aug 15

Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Jan 11
Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Aug 18
Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Apr 12
Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

Mar 08
Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

Jan 15
The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

CEO Compensation Analysis

How has Fred Chereau's remuneration changed compared to LogicBio Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$31m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$2mUS$543k

-US$40m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$2mUS$479k

-US$33m

Sep 30 2020n/an/a

-US$37m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$633kUS$510k

-US$40m

Sep 30 2019n/an/a

-US$32m

Jun 30 2019n/an/a

-US$29m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$2mUS$411k

-US$18m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$11m

Mar 31 2018n/an/a

-US$9m

Dec 31 2017US$779kUS$385k

-US$8m

Compensation vs Market: Fred's total compensation ($USD2.23M) is above average for companies of similar size in the US market ($USD750.11K).

Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.

CEO

Fred Chereau (55 yo)

6.6yrs

Tenure

US$2,228,208

Compensation

Mr. Frederic Chereau, M.B.A., also known as Fred, is the Chairman of the Board of Coave Therapeutics since October 2022 and has been its Independent Non-Executive Director since October 2021. He has execut...

Leadership Team

NamePositionTenureCompensationOwnership
Frederic Chereau
President6.6yrsUS$2.23m0.77%
$ 525.4k
Mark Kay
Co-Founderno dataUS$156.64k2.38%
$ 1.6m
Daniel Gruskin
Chief Medical Officer2.4yrsUS$1.54m0.010%
$ 6.9k
Leszek Lisowski
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Adi Barzel
Co-Founder8.3yrsno datano data
Joshua Blacher
Interim CFOless than a yearno datano data
Matthias Hebben
Global VP & Head of Technology Development3.6yrsno datano data
Mariana Nacht
Chief Scientific Officer2yrsUS$1.34mno data
Andrea Paul
General Counsel & Corporate Secretary1.5yrsno datano data
Grace Lochhead
VP & Head of Human Resources1.2yrsno datano data
Janice Olson
Senior Vice President of Strategy & Portfolio Management1.4yrsno datano data
Michael Franken
Chief Business Officer1.3yrsno datano data

1.8yrs

Average Tenure

55yo

Average Age

Experienced Management: LOGC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Frederic Chereau
Presidentno dataUS$2.23m0.77%
$ 525.4k
Mark Kay
Co-Founder6.8yrsUS$156.64k2.38%
$ 1.6m
Leszek Lisowski
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Michael Wyzga
Independent Director4.2yrsUS$87.39k0.0095%
$ 6.5k
Richard Moscicki
Independent Chairman of the Board4.1yrsUS$113.64k0.012%
$ 8.1k
Mark Enyedy
Independent Director2.7yrsUS$82.02k0.0089%
$ 6.0k
Markus Grompe
Member of Scientific Advisory Boardno datano datano data
Leon Chen
Independent Director6.8yrsUS$81.14k0.068%
$ 46.2k
J. Goater
Independent Director1.9yrsUS$76.77k0%
$ 0
Daphne Karydas
Independent Director1.9yrsUS$79.64k0%
$ 0
David Russell
Member of Scientific Advisory Boardno datano datano data
Susan Kahn
Independent Directorless than a yearUS$40.31kno data

3.4yrs

Average Tenure

58yo

Average Age

Experienced Board: LOGC's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/16 12:09
End of Day Share Price 2022/11/15 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LogicBio Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Gbolahan Amusa BenzChardan Capital Markets, LLC
Silvan TuerkcanCitizens JMP Securities, LLC